CDK9-IN-10

Target: This ligand targets cyclin-dependent kinase 9 (CDK9) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for cyclin-dependent kinase 9 (CDK9). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings cyclin-dependent kinase 9 (CDK9) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• CDK9 PROTAC Degradation: CDK9-IN-10 can be used as a targeting ligand within PROTAC designs to recruit E3 ligases and drive selective degradation of CDK9. This enables mechanistic studies of CDK9 turnover, transcriptional elongation control, and dependence of gene expression programs on CDK9 protein abundance.

• Transcription Elongation Studies: Incorporating CDK9-IN-10 into PROTACs supports experiments probing how rapid loss of CDK9 affects RNA polymerase II processivity. Researchers can evaluate changes in phosphorylation states, nascent transcript production, and global transcriptional responses to distinguish degradation-driven effects from reversible kinase inhibition.

• E3 Ligase Recruitment Optimization: CDK9-IN-10 is suitable for systematic PROTAC optimization by varying linker length, attachment sites, and E3 ligase ligands. This approach can tune ternary complex formation and degradation efficiency, allowing identification of configurations that maximize CDK9 ubiquitination and proteasome-dependent turnover.

• Resistance Mechanism Mapping: CDK9-IN-10-based PROTACs can be applied to study cellular resistance to CDK9 pathway perturbation by comparing degradation versus inhibition outcomes. By monitoring CDK9 levels, downstream transcription markers, and compensatory signaling, researchers can map adaptive responses and degradation-specific escape routes.

CDK9-IN-10 is a CDK kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of CDK9-IN-10 is characterized by phenol or alcohol functionality. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.